Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Homomultimeric FAP Inhibitor-Based Radioligands for Cancer Theranostics: Design Principles, Structure-Function Relationships, and Preclinical Performance.

Molecules (Basel, Switzerland)·2026
Same author

Preclinical Evaluation of a <sup>177</sup>Lu-Labeled Gastrin-Releasing Peptide Receptor Antagonist and Prostate Cancer Treatment with Monotherapy and in Combination with Everolimus.

ACS pharmacology & translational science·2026
Same author

A true theranostic pair - <sup>44/47</sup>Sc-labeled GRPR antagonist shows great promise for managing prostate and breast cancer.

European journal of nuclear medicine and molecular imaging·2025
Same author

Preclinical evaluation of DOTAGA.Glu.(FAPI)<sub>2</sub> and DO3A.Glu.(FAPI)<sub>2</sub> as theranostics with human dosimetry extrapolation to lutetium-177 and terbium-161 analogs.

European journal of nuclear medicine and molecular imaging·2025
Same author

Improved FAPI-radiopharmaceutical pharmacokinetics from the perspectives of a dose escalation study.

European journal of nuclear medicine and molecular imaging·2025
Same author

Tailoring Fibroblast-Activation Protein Targeting for Theranostics: A Comparative Preclinical Evaluation of the <sup>68</sup>Ga- and <sup>177</sup>Lu-Labeled Monomeric and Dimeric Fibroblast-Activation Protein Inhibitors DOTA.SA.FAPi and DOTAGA.(SA.FAPi)<sub>2</sub>.

Molecules (Basel, Switzerland)·2024
Same journal

RETRACTED: Atta et al. Effect of Montmorillonite Nanogel Composite Fillers on the Protection Performance of Epoxy Coatings on Steel Pipelines. <i>Molecules</i> 2017, <i>22</i>, 905.

Molecules (Basel, Switzerland)·2026
Same journal

Correction: Chen et al. Chemical Composition of <i>Litsea pungens</i> Essential Oil and Its Potential Antioxidant and Antimicrobial Activities. <i>Molecules</i> 2023, <i>28</i>, 6835.

Molecules (Basel, Switzerland)·2026
Same journal

Correction: Ruan et al. Comparison of Extraction, Isolation, Purification, Structural Characterization and Immunomodulatory Activity of Polysaccharides from Two Species of <i>Cistanche</i>. <i>Molecules</i> 2025, <i>30</i>, 4754.

Molecules (Basel, Switzerland)·2026
Same journal

Correction: Li et al. Gastrodin Ameliorates Cognitive Dysfunction in Vascular Dementia Rats by Suppressing Ferroptosis via the Regulation of the Nrf2/Keap1-GPx4 Signaling Pathway. <i>Molecules</i> 2022, <i>27</i>, 6311.

Molecules (Basel, Switzerland)·2026
Same journal

Correction: Zueva et al. Steady-State Kinetics of Enzyme-Catalyzed Hydrolysis of Echothiophate, a P-S Bonded Organophosphorus as Monitored by Spectrofluorimetry. <i>Molecules</i> 2020, <i>25</i>, 1371.

Molecules (Basel, Switzerland)·2026
Same journal

1,4-Diazatriphenylene and Its Hetero-Fused Analogs: Synthesis and Applications.

Molecules (Basel, Switzerland)·2026
See all related articles

Related Experiment Video

Updated: Mar 5, 2026

Synthesis of 68Ga Core-doped Iron Oxide Nanoparticles for Dual Positron Emission Tomography /T1Magnetic Resonance Imaging
07:26

Synthesis of 68Ga Core-doped Iron Oxide Nanoparticles for Dual Positron Emission Tomography /T1Magnetic Resonance Imaging

Published on: November 20, 2018

7.0K

Metal-Based PSMA Radioligands.

Eleni Gourni1,2, Gjermund Henriksen3,4,5

  • 1Institute of Basic Medical Sciences, University of Oslo, Oslo 0372, Norway. eleni.gourni@medisin.uio.no.

Molecules (Basel, Switzerland)
|March 25, 2017
PubMed
Summary
This summary is machine-generated.

Prostate specific membrane antigen (PSMA) is a key target for advanced prostate cancer imaging and therapy. Metal-based PSMA radioligands show significant promise for improving patient management in nuclear medicine.

Keywords:
PETSPECTintraoperative applications.prostate specific membrane antigen (PSMA)radionuclide therapy

More Related Videos

Detection and Recovery of Palladium, Gold and Cobalt Metals from the Urban Mine Using Novel Sensors/Adsorbents Designated with Nanoscale Wagon-wheel-shaped Pores
10:31

Detection and Recovery of Palladium, Gold and Cobalt Metals from the Urban Mine Using Novel Sensors/Adsorbents Designated with Nanoscale Wagon-wheel-shaped Pores

Published on: December 6, 2015

28.7K
Investigations on the GaIII Complex of EOB-DTPA and Its 68Ga Radiolabeled Analogue
11:22

Investigations on the GaIII Complex of EOB-DTPA and Its 68Ga Radiolabeled Analogue

Published on: August 17, 2016

10.6K

Related Experiment Videos

Last Updated: Mar 5, 2026

Synthesis of 68Ga Core-doped Iron Oxide Nanoparticles for Dual Positron Emission Tomography /T1Magnetic Resonance Imaging
07:26

Synthesis of 68Ga Core-doped Iron Oxide Nanoparticles for Dual Positron Emission Tomography /T1Magnetic Resonance Imaging

Published on: November 20, 2018

7.0K
Detection and Recovery of Palladium, Gold and Cobalt Metals from the Urban Mine Using Novel Sensors/Adsorbents Designated with Nanoscale Wagon-wheel-shaped Pores
10:31

Detection and Recovery of Palladium, Gold and Cobalt Metals from the Urban Mine Using Novel Sensors/Adsorbents Designated with Nanoscale Wagon-wheel-shaped Pores

Published on: December 6, 2015

28.7K
Investigations on the GaIII Complex of EOB-DTPA and Its 68Ga Radiolabeled Analogue
11:22

Investigations on the GaIII Complex of EOB-DTPA and Its 68Ga Radiolabeled Analogue

Published on: August 17, 2016

10.6K

Area of Science:

  • Nuclear Medicine
  • Oncology
  • Radiochemistry

Background:

  • Prostate cancer is a common malignancy with significant advancements in molecular targeting for in vivo imaging and therapy.
  • Prostate specific membrane antigen (PSMA), a type II integral membrane protein, is overexpressed on prostate cancer cells, correlating with tumor stage and progression, particularly in advanced and metastatic disease.

Purpose of the Study:

  • To review the development and applications of metal-based prostate specific membrane antigen (PSMA) radioligands.
  • To highlight the impact of PSMA-based radioligands in nuclear medicine for prostate cancer management.

Main Methods:

  • Review of literature on chelating-based PSMA-specific ligands.
  • Analysis of radiometal labeling for diagnostic (SPECT, PET) and therapeutic applications.
  • Exploration of intraoperative uses of PSMA radioligands.

Main Results:

  • PSMA is a validated target for prostate cancer, especially in advanced stages.
  • Various radiometals have been successfully chelated to PSMA-specific ligands.
  • PSMA radioligands are utilized in SPECT, PET, targeted radionuclide therapy, and intraoperative settings.

Conclusions:

  • Metal-based PSMA radioligands represent a significant advancement in prostate cancer diagnostics and therapeutics.
  • These agents offer substantial potential to improve the clinical management of prostate cancer patients.
  • Further development and application of PSMA radioligands are crucial for precision oncology.